Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF) welcomes formal results of a comparative study showing its DurAVR™ transcatheter aortic valve restoring ascending aortic blood flow in five patients who received its aortic valve in the first-in-human trial.
The study compared DurAVR™ to normal age-height-weight matched controls, other transcatheter aortic valve implants (TAVI) and patients who had surgical aortic valve replacement (SAVR).
Results revealed in London
The study results, which were presented by the University of East Anglia’s Associate Professor in Cardiology, Dr Pankaj Garg, at the annual PCR London Valves 2022 Congress from November 27-29, showed that SAVR and other TAVI valves did not demonstrate the same physiological advantage.
“Restoration of normal laminal aortic flow is emerging as a novel target mainly to reduce energy loss in the cardiovascular system. Abnormal flow, including eccentric flow, is associated with continued aortic dilatation which will further warrant intervention,” said Garg, who quantified the key heart valve performance parameters in the ascending aorta using phase-contrast MRI, a non-invasive method for imaging blood and tissue velocity.
“Furthermore, as TAVI is being offered to younger cohorts, restoration of normal laminar aortic flow is an important therapeutic goal. DurAVR™ THV architecture appears to restore normal aortic flow,” said the professor, who is also a consultant cardiologist at Norfolk and Norwich University Hospital.
Anteris chief executive officer Wayne Paterson added: “Future studies are warranted to investigate the prognostic importance of restoration of normal aortic flow in this patient population, but this preliminary data reveals the unique design characteristics of DurAVR™ are potentially redefining how aortic heart valve performance is benchmarked.”
Game-changing treatment
Anteris is a structural heart company that delivers clinically superior and durable solutions through better science and better design. Its focus is developing next-generation technologies that help healthcare professionals deliver consistent life-changing outcomes for patients.
Anteris’ DurAVR™ 3D single-piece aortic heart valve replacement addresses the needs of younger and more active aortic stenosis patients by delivering superior performance and durability through innovations designed to last the remainder of a patient’s lifetime.
The proven benefits of its patented ADAPT® tissue technology, paired with the unique design of the DurAVR™ 3D single-piece aortic heart valve, have the potential to deliver a game-changing treatment to aortic stenosis patients worldwide and provide a much-needed solution to the challenges facing doctors.